Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-28T12:53:48.611Z Has data issue: false hasContentIssue false
  • English
  • Français

The effects of galangin in prepulse inhibition test and experimental schizophrenia models

Published online by Cambridge University Press:  20 October 2021

Bilgin Kaygisiz Open the ORCID record for Bilgin Kaygisiz [Opens in a new window] ,
Sule Aydin ,
Engin Yildirim ,
Ahmet Musmul ,
Kevser Erol  and
Fatma Sultan Kilic
Bilgin Kaygisiz*
Affiliation:
Faculty of Medicine, Department of Medical Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey
Sule Aydin
Affiliation:
Faculty of Medicine, Department of Medical Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey
Engin Yildirim
Affiliation:
Faculty of Medicine, Department of Medical Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey
Ahmet Musmul
Affiliation:
Faculty of Medicine, Department of Biostatistics, Eskisehir Osmangazi University, Eskisehir, Turkey
Kevser Erol
Affiliation:
Faculty of Medicine, Department of Medical Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey
Fatma Sultan Kilic
Affiliation:
Faculty of Medicine, Department of Medical Pharmacology, Eskisehir Osmangazi University, Eskisehir, Turkey
*
Author for correspondence: Bilgin Kaygisiz, Email: bilginkay@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Acetylcholinesterase inhibitors are the focus of interest in the management of schizophrenia. We aimed to investigate the effects of acute galangin administration, a flavonoid compound with acetylcholinesterase inhibiting activity, on schizophrenia-associated cognitive deficits in rats and schizophrenia models in mice.

Methods:

Apomorphine-induced prepulse inhibition (PPI) disruption for cognitive functions, nicotinic, muscarinic, and serotonergic mechanism involvement, and brain acetylcholine levels were investigated in Wistar rats. Apomorphine-induced climbing, MK-801-induced hyperlocomotion, and catalepsy tests were used as schizophrenia models in Swiss albino mice. The effects of galangin were compared with acetylcholinesterase inhibitor donepezil, and typical and atypical antipsychotics haloperidol and olanzapine, respectively.

Results:

Galangin (50,100 mg/kg) enhanced apomorphine-induced PPI disruption similar to donepezil, haloperidol, and olanzapine (p < 0.05). This effect was not altered in the combination of galangin with the nicotinic receptor antagonist mecamylamine (1 mg/kg), the muscarinic receptor antagonist scopolamine (0.05 mg/kg), or the serotonin-1A receptor antagonist WAY-100635 (1 mg/kg) (p > 0.05). Galangin (50,100 mg/kg) alone increased brain acetylcholine concentrations (p < 0.05), but not in apomorphine-injected rats (p > 0.05). Galangin (50 mg/kg) decreased apomorphine-induced climbing and MK-801-induced hyperlocomotion similar to haloperidol and olanzapine (p < 0.05), but did not induce catalepsy, unlike them.

Conclusion:

We suggest that galangin may help enhance schizophrenia-associated cognitive deficits, and nicotinic, muscarinic cholinergic, and serotonin-1A receptors are not involved in this effect. Galangin also exerted an antipsychotic-like effect without inducing catalepsy and may be considered as an advantageous antipsychotic agent.

Keywords

cognitive functionflavonoidexperimental animal modelsprepulse inhibitionschizophrenia
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 34 , Issue 1 , February 2022 , pp. 37 - 46
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abudukeyoumu, N, Hernandez-Flores, T, Garcia-Munoz, M and Arbuthnott, GW (2019) Cholinergic modulation of striatal microcircuits. European Journal of Neuroscience 49(5), 604–622.10.1111/ejn.13949CrossRefGoogle ScholarPubMed
Ago, Y, Takuma, K and Matsuda, T (2014) Potential role of serotonin1A receptors in post-weaning social isolation-induced abnormal behaviors in rodents. Journal of Pharmacological Sciences 125(3), 237–241.CrossRefGoogle ScholarPubMed
Akhtar, M, Uma Devi, P, Ali, A, Pillai, KK and Vohora, D (2006) Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundamental & Clinical Pharmacology 20(4), 373–378.CrossRefGoogle ScholarPubMed
Ballmaier, M, Casamenti, F, Scali, C, Mazzoncini, R, Zoli, M, Pepeu, G and Spano, PF (2002) Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 114(1), 91–98.CrossRefGoogle ScholarPubMed
Bardgett, ME, Boeckman, R, Krochmal, D, Fernando, H, Ahrens, R and Csernansky, JG (2003) NMDA receptor blockade and hippocampal neuronal loss impair fear conditioning and position habit reversal in C57Bl/6 mice. Brain Research Bulletin 60(1-2), 131–142.CrossRefGoogle ScholarPubMed
Brimblecombe, KR, Threlfell, S, Dautan, D, Kosillo, P, Mena-Segovia, J and Cragg, SJ (2018) Targeted activation of cholinergic interneurons accounts for the modulation of dopamine by striatal nicotinic receptors. eNeuro 5(5), 0397-17.2018.CrossRefGoogle ScholarPubMed
Bora, E, Veznedaroğlu, B and Kayahan, B (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clinical Neuropharmacology 28(3), 139–141.CrossRefGoogle ScholarPubMed
Buchanan, RW, Conley, RR, Dickinson, D, Ball, MP, Feldman, S, Gold, JM and McMahon, RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. American Journal of Psychiatry 165(1), 82–89.10.1176/appi.ajp.2007.07050724CrossRefGoogle ScholarPubMed
Canal, CE, Morgan, D, Felsing, D, Kondabolu, K, Rowland, NE, Robertson, KL, Sakhuja, R and Booth, RG (2014) A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses. Journal of Pharmacology and Experimental Therapeutics 349(2), 310–318.CrossRefGoogle ScholarPubMed
Chang, WL, Weber, M, Breier, MR, Saint Marie, RL, Hines, SR and Swerdlow, NR (2012) Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research 1437, 69–76.10.1016/j.brainres.2011.12.007CrossRefGoogle ScholarPubMed
Chen, F, Tan, YF, Li, HL, Qin, ZM, Cai, HD, Lai, WY, Zhang, XP, Li, YH, Guan, WW, Li, YB, Zhang, JQ (2015) Differential systemic exposure to galangin after oral and intravenous administration to rats. Chemistry Central Journal 9(1), 1152.CrossRefGoogle ScholarPubMed
Chien, ST, Shi, MD, Lee, YC, Te, CC and Shih, YW (2015) Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells. Cancer Cell International 15, 15.CrossRefGoogle ScholarPubMed
Chʼng, SS, Walker, AJ, McCarthy, M, Le, TK, Thomas, N, Gibbons, A, Udawela, M, Kusljic, S, Dean, B, Gogos, A (2020) The impact of removal of ovarian hormones on cholinergic muscarinic receptors: examining prepulse inhibition and receptor binding. Brain Sciences 10(2), 106.CrossRefGoogle ScholarPubMed
Chow, CL, Kadouh, NK, Bostwick, JR and VandenBerg, AM (2020) Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. Pharmacotherapy 40(6), 565–574.CrossRefGoogle ScholarPubMed
Conti, LH (2012) Interactions between corticotropin-releasing factor and the serotonin 1A receptor system on acoustic startle amplitude and prepulse inhibition of the startle response in two rat strains. Neuropharmacology 62(1), 256–263.CrossRefGoogle ScholarPubMed
D’Souza, MS and Markou, A (2012) Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 62(3), 1564–1573.CrossRefGoogle ScholarPubMed
Dulawa, SC and Geyer, MA (2000) Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology 39(11), 2170–2179.CrossRefGoogle ScholarPubMed
Dyer, MA, Freudenreich, O, Culhane, MA, Pachas, GN, Deckersbach, T, Murphy, E, Goff, DC and Evins, AE (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophrenia Research 102, 88–95.CrossRefGoogle ScholarPubMed
Erskine, D, Taylor, JP, Bakker, G, Brown, AJH, Tasker, T and Nathan, PJ (2019) Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discovery Today 24(12), 2307–2314.CrossRefGoogle ScholarPubMed
Fan, HR, Du, WF, Zhu, T, Wu, YJ, Liu, YM, Wang, Q, Wang, Q, Gu, X, Shan, X, Deng, S, Zhu, T, Xu, TL, Ge, WH, Li, WG, Li, F (2018) Quercetin reduces cortical GABAergic transmission and alleviates MK-801-induced hyperactivity. EBioMedicine 34, 201–213.CrossRefGoogle ScholarPubMed
Fang, D, Xiong, Z, Xu, J, Yin, J and Luo, R (2019) Chemopreventive mechanisms of galangin against hepatocellular carcinoma: a review. Biomedicine & Pharmacotherapy 109, 2054–2061.CrossRefGoogle ScholarPubMed
Geyer, MA, Swerdlow, NR, Lehmann-Masten, V, Teschendorf, HJ, Traut, M and Gross, G (1999) Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. Journal of Pharmacology and Experimental Therapeutics 290(2), 716–724.Google ScholarPubMed
Ghezzi, L, Scarpini, E and Galimberti, D (2013) Disease-modifying drugs in Alzheimer’s disease. Drug Design, Development and Therapy 7, 1471–1478.Google ScholarPubMed
Gobira, PH, Ropke, J, Aguiar, DC, Crippa, JA and Moreira, FA (2013) Animal models for predicting the efficacy and side effects of antipsychotic drugs. Brazilian Journal of Psychiatry 35(Suppl 2), S132–S139.CrossRefGoogle ScholarPubMed
Guo, AJ, Xie, HQ, Choi, RC, Zheng, KY, Bi, CW, Xu, SL, Dong, TT and Tsim, KW (2010) Galangin, a flavonol derived from Rhizoma Alpiniae officinarum, inhibits acetylcholinesterase activity in vitro. Chemico-Biological Interactions 187(1-3), 246–248.CrossRefGoogle ScholarPubMed
Hoffman, DC and Donovan, H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl) 120(2), 128–133.10.1007/BF02246184CrossRefGoogle ScholarPubMed
Hohnadel, E, Bouchard, K and Terry, AV Jr (2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52(2), 542–551.CrossRefGoogle ScholarPubMed
Jin, J, Cheng, J, Lee, KW, Amreen, B, McCabe, KA, Pitcher, C, Liebmann, T, Greengard, P and Flajolet, M (2019) Cholinergic neurons of the medial septum are crucial for sensorimotor gating. Journal of Neuroscience 39(26), 5234–5242.CrossRefGoogle ScholarPubMed
Jones, CK and Shannon, HE (2000) Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. European Journal of Pharmacology 391(1-2), 105–112.10.1016/S0014-2999(00)00055-8CrossRefGoogle ScholarPubMed
Jones, CK, Eberle, EL, Shaw, DB, McKinzie, DL and Shannon, HE (2005) Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. Journal of Pharmacology and Experimental Therapeutics 312(3), 1055–1063.CrossRefGoogle ScholarPubMed
Jung, YC, Kim, ME, Yoon, JH, Park, PR, Youn, HY, Lee, HW and Lee, JS (2014) Anti-inflammatory effects of galangin on lipopolysaccharide-activated macrophages via ERK and NF-κB pathway regulation. Immunopharmacology and Immunotoxicology 36(6), 426–432.CrossRefGoogle ScholarPubMed
Jones, CK, Byun, N and Bubser, M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37(1), 16–42.CrossRefGoogle ScholarPubMed
Koukouli, F, Rooy, M, Tziotis, D, Sailor, KA, OʼNeill, HC, Levenga, J, Witte, M, Nilges, M, Changeux, JP, Hoeffer, CA, Stitzel, JA, Gutkin, BS, DiGregorio, DA, Maskos, U (2017) Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. Nature Medicine 23(3), 347–354.CrossRefGoogle Scholar
Khoja, S, Asatryan, L, Jakowec, MW and Davies, DL (2019) Dopamine receptor blockade attenuates purinergic P2X4 receptor mediated prepulse inhibition deficits and underlying molecular mechanisms. Frontiers in Cellular Neuroscience 13, 331.CrossRefGoogle ScholarPubMed
Kinsey, SG and Cole, EC (2013) Acute Δ(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal anti-inflammatory drug diclofenac sodium in mice. European Journal of Pharmacology 715(1-3), 111–116.CrossRefGoogle ScholarPubMed
Koda, K, Ago, Y, Kawasaki, T, Hashimoto, H, Baba, A and Matsuda, T (2008) Galantamine and donepezil differently affect isolation rearing induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 196(2), 293–301.CrossRefGoogle ScholarPubMed
Koda, K, Ago, Y, Yano, K, Nishimura, M, Kobayashi, H, Fukada, A, Takuma, K and Matsuda, T (2011) Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation. British Journal of Pharmacology 162(3), 763–772.CrossRefGoogle ScholarPubMed
Kohnomi, S, Suemaru, K, Goda, M, Choshi, T, Hibino, S, Kawasaki, H and Araki, H (2010) Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats. Brain Research 1353(5), 152–158.CrossRefGoogle ScholarPubMed
Krebs-Thomson, K, Ruiz, EM, Masten, V, Buell, M and Geyer, MA (2006) The roles of 5-HT1A and 5-HT2 receptors inthe effects of 5-MeO DMT on locomotor activity andprepulse inhibition in rats. Psychopharmacology 189(3), 319–329.CrossRefGoogle Scholar
Kumar, PNS, Mohemmedali, SP, Anish, PK and Andrade, C (2017) Cognitive effects with rivastigmine augmentation of risperidone: a 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Indian Journal of Psychiatry 59(2), 219–224.CrossRefGoogle Scholar
Larrauri, JA, Burke, DA, Hall, BJ and Levin, ED (2015) Role of nicotinic receptors in the lateral habenula in the attenuation of amphetamine-inducedprepulse inhibition deficits of the acoustic startle response in rats. Psychopharmacology (Berl) 232(16), 3009–3017.10.1007/s00213-015-3940-zCrossRefGoogle ScholarPubMed
Laruelle, M (2014) Schizophrenia: from dopaminergic to glutamatergic interventions. Current Opinion in Pharmacology 14, 97–102.CrossRefGoogle ScholarPubMed
Madireddy, S and Madireddy, S (2020) Regulation of reactive oxygen species-mediated damage in the pathogenesis of schizophrenia. Brain Sciences 10(10), 742.10.3390/brainsci10100742CrossRefGoogle ScholarPubMed
Mahmood, D, Khanam, R, Pillai, KK and Akhtar, M (2012) Protective effects of histamine H3 receptor ligands in schizophrenic behaviors in experimental models. Pharmacological Reports 64(1), 191–204.Google ScholarPubMed
Matsuda, T (2013) Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan. Biological and Pharmaceutical Bulletin 36(12), 1871–1882.CrossRefGoogle ScholarPubMed
Myslivecek, J (2021) Two players in the field: hierarchical model of interaction between the dopamine and acetylcholine signaling systems in the striatum. Biomedicines 9(1), 25.CrossRefGoogle ScholarPubMed
Neves, G, Antonio, CB, Betti, AH, Pranke, MA, Fraga, CA, Barreiro, EJ, Noël, F and Rates, SM (2013) New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research 237, 86–95.10.1016/j.bbr.2012.09.016CrossRefGoogle ScholarPubMed
Pinnock, F, Bosch, D, Brown, T, Simons, N, Yeomans, JR, DeOliveira, C and Schmid, S (2015) Nicotine receptors mediating sensorimotor gating and its enhancement by systemic nicotine. Frontiers in Behavioral Neuroscience 9, 369.CrossRefGoogle ScholarPubMed
Pohanka, M (2014) Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. International Journal of Molecular Science 15(6), 9809–9825.10.3390/ijms15069809CrossRefGoogle ScholarPubMed
Poje, AB and Filion, DL (2017) The effects of multiphasic prepulses on automatic and attention-modulated prepulse inhibition. Cognitive Processing 18(3), 261–270.CrossRefGoogle ScholarPubMed
Rodvelt, KR, Kracke, GR, Schachtman, TR and Miller, DK (2008) Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices. Pharmacology Biochemistry and Behaviour 91(1), 71–76.CrossRefGoogle ScholarPubMed
Santos, B, González-Fraile, E, Zabala, A, Guillén, V, Rueda, JR and Ballesteros, J (2018) Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. Journal of Psychopharmacology 32(11), 1155–1166.CrossRefGoogle Scholar
Sato, K (2020) Why is prepulse inhibition disrupted in schizophrenia? Medical Hypotheses 143, 109901.CrossRefGoogle ScholarPubMed
Scarr, E, Gibbons, AS, Neo, J, Udawela, M and Dean, B (2013) Cholinergic connectivity: it’s implications for psychiatric disorders. Frontiers in Cellular Neuroscience 7, 55.10.3389/fncel.2013.00055CrossRefGoogle ScholarPubMed
Singh, M, Kaur, M and Silakari, O (2014) Flavones: an important scaffold for medicinal chemistry. European Journal of Medicinal Chemistry 84, 206–239.CrossRefGoogle ScholarPubMed
Sławińska, A, Wierońska, JM, Stachowicz, K, Marciniak, M, Lasoń-Tyburkiewicz, M, Gruca, P, Papp, M, Kusek, M, Tokarski, K, Doller, D, Pilc, A (2013) The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents. British Journal of Pharmacology 169(8), 1824–1839.CrossRefGoogle ScholarPubMed
Sukhanov, I, Espinoza, S, Yakovlev, DS, Hoener, MC, Sotnikova, TD and Gainetdinov, RR (2014) TAAR1-dependent effects of apomorphine in mice. International Journal of Neuropsychopharmacology 17(10), 1683–1693.CrossRefGoogle ScholarPubMed
Tai, YM, Ko, CY, Lin, CC, Wan, YY, Chung, JY and Liu, YP (2018) Effects of 5HT1A activation on gating profile following 5HT depletion in rats lacking social attachment since weanling. Psychiatry Investigation 15(2), 193–199.10.30773/pi.2017.05.14.2CrossRefGoogle ScholarPubMed
Uno, Y and Coyle, JT (2019) Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences 73(5), 204–215.CrossRefGoogle Scholar
Uslu, G, Savci, V, Buyukuysal, LR and Goktalay, G (2014) CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism. Neuroscience Letters 569, 153–157.CrossRefGoogle ScholarPubMed
Wadenberg, MG, Manetti, D, Romanelli, MN and Arias, HR (2017) Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat. Behavioural Brain Research 333, 129–134.CrossRefGoogle ScholarPubMed
Wang, L, Zhang, Y, Wang, C, Zhang, X, Wang, Z, Liang, X, Alachkar, A and Civelli, O (2019) A natural product with high affinity to sigma and 5-HT7 receptors as novel therapeutic drug for negative and cognitive symptoms of schizophrenia. Neurochemical Research 44(11), 2536–2545.10.1007/s11064-019-02873-7CrossRefGoogle ScholarPubMed
Yoshida, K and Takeuchi, H (2021) Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behavioural Brain Research 402, 113098.CrossRefGoogle Scholar
Zanoaga, O, Braicu, C, Jurj, A, Rusu, A, Buiga, R and Berindan-Neagoe, I (2019) Progress in research on the role of flavonoids in lung cancer. International Journal of Molecular Sciences 20(17), 4291.CrossRefGoogle ScholarPubMed
Zappettini, S, Grilli, M, Olivero, G, Chen, J, Padolecchia, C, Pittaluga, A, Tomé, AR, Cunha, RA and Marchi, M (2014) Nicotinic α7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens. Frontiers in Cellular Neuroscience 8, 332.CrossRefGoogle ScholarPubMed
Zhang, C, Liu, X, Zhou, P, Zhang, J, He, W and Yuan, TF (2018) Cholinergic tone in ventral tegmental area: functional organization and behavioral implications. Neurochemistry International 114, 127–133.CrossRefGoogle ScholarPubMed
Zhang, W, Yamada, M, Gomeza, J, Basile, AS and Wess, J (2002) Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. Journal of Neuroscience 22(15), 6347–6352.CrossRefGoogle ScholarPubMed